Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a targeted drug hit the mark against HER2-mutated lung cancer?

NCT ID NCT06114511

Recruiting now Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This trial is testing an experimental drug called BL-M07D1 in people with a specific type of advanced non-small cell lung cancer that has a HER2 mutation. The study aims to find the best dose and see how well the drug shrinks tumors, while also checking for side effects. Participants receive the drug through an IV infusion.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental antibody-drug conjugate called BL-M07D1
What this could lead to
If successful, this could provide a new targeted treatment option for people with HER2-mutated non-small cell lung cancer.
What could go wrong
This is an early-phase trial, so the drug may not prove effective or could cause significant side effects. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Sun Yat-sen University Cancer Center

    RECRUITING

    Guangzhou, Guangdong, China

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.